← All trials
NCT05259033
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 11, 2022
- Primary completion
- Dec 13, 2023
- Completion date
- Jan 16, 2024
- First posted
- Feb 28, 2022
- Last posted
- Jul 19, 2024
- Enrollment
- 683
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Novo NordiskLead sponsor
- Novo NordiskOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.